ezetimibe has been researched along with Hyperinsulinism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Y; Liang, Y; Liu, S; Ren, Q; Wang, X; Wu, T | 1 |
| Austin, TM; Cook, JA; Davis, HR; Farley, C; Tetzloff, GG; van Heek, M | 1 |
2 other study(ies) available for ezetimibe and Hyperinsulinism
| Article | Year |
|---|---|
Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
Topics: Acetyl-CoA Carboxylase; Animals; Anticholesteremic Agents; Azetidines; CD36 Antigens; Diet, High-Fat; Ezetimibe; Fatty Acids; Fibrosis; Hyperinsulinism; Insulin Resistance; Lipid Metabolism; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Stearoyl-CoA Desaturase | 2014 |
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Ezetimibe; Hypercholesterolemia; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Liver; Mesocricetus; Obesity; Triglycerides | 2001 |